Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590931304> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2590931304 endingPage "698" @default.
- W2590931304 startingPage "698" @default.
- W2590931304 abstract "698 Background: In metastatic colorectal cancer (mCRC) patients with isolated liver metastases, surgical resection offers the greatest likelihood of cure. Whilst for mCRC patients treated with palliative intent the addition of bevacizumab to the chemotherapy backbone is of proven benefit, whether to use bevacizumab in the resectable or potentially resectable population is a clinical dilemma. Methods: Consecutive patients who underwent resection of liver metastases were identified from a prospective Australian mCRC registry that captures comprehensive data on patient and tumor characteristics (including resectability), treatment and outcome. The use of bevacizumab in this setting was examined and the impact on outcomes was explored. Results: From a total mCRC population of 1,700 patients, 543 patients with liver-only mCRC were identified, of which 217 patients (40%) underwent liver resection. Perioperative chemotherapy was administered to 185 patients (85.3%), with bevacizumab added to chemotherapy in 73 (39.5%) patients. There was a trend for bevacizumab treated patients to be younger (median age 60.4 vs 65.1 years, p = 0.07) and fitter (mean Charlson score 2.22 vs 2.64, p = 0.054). Patients that received bevacizumab with perioperative chemotherapy were considerably less likely to have disease regarded as resectable at diagnosis (39 of 73 (53.4%) vs 95 of 112 (84.8%), p =<.01). At 5 years, overall survival was similar for bevacizumab treated and non-treated patients (61.4% vs. 59.2%, HR 0.83, p=0.52). There were no deaths within 30 days of surgery in any patients. Conclusions: Despite limited evidence to support the use of bevacizumab in patients with resectable or potentially resectable liver-only mCRC, clinicians are not infrequently utilising this approach, particularly in younger and fitter patients and those not considered to have resectable disease at diagnosis. The addition of bevacizumab did not appear to impact survival outcomes. A multivariate analysis is underway to better define the impact of bevacizumab on survival outcomes." @default.
- W2590931304 created "2017-03-03" @default.
- W2590931304 creator A5007132576 @default.
- W2590931304 creator A5015015784 @default.
- W2590931304 creator A5015610217 @default.
- W2590931304 creator A5020220461 @default.
- W2590931304 creator A5047478386 @default.
- W2590931304 creator A5054979658 @default.
- W2590931304 creator A5085096262 @default.
- W2590931304 creator A5086640363 @default.
- W2590931304 creator A5089420153 @default.
- W2590931304 creator A5090229354 @default.
- W2590931304 date "2016-02-01" @default.
- W2590931304 modified "2023-09-25" @default.
- W2590931304 title "Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice." @default.
- W2590931304 doi "https://doi.org/10.1200/jco.2016.34.4_suppl.698" @default.
- W2590931304 hasPublicationYear "2016" @default.
- W2590931304 type Work @default.
- W2590931304 sameAs 2590931304 @default.
- W2590931304 citedByCount "0" @default.
- W2590931304 crossrefType "journal-article" @default.
- W2590931304 hasAuthorship W2590931304A5007132576 @default.
- W2590931304 hasAuthorship W2590931304A5015015784 @default.
- W2590931304 hasAuthorship W2590931304A5015610217 @default.
- W2590931304 hasAuthorship W2590931304A5020220461 @default.
- W2590931304 hasAuthorship W2590931304A5047478386 @default.
- W2590931304 hasAuthorship W2590931304A5054979658 @default.
- W2590931304 hasAuthorship W2590931304A5085096262 @default.
- W2590931304 hasAuthorship W2590931304A5086640363 @default.
- W2590931304 hasAuthorship W2590931304A5089420153 @default.
- W2590931304 hasAuthorship W2590931304A5090229354 @default.
- W2590931304 hasConcept C121608353 @default.
- W2590931304 hasConcept C126322002 @default.
- W2590931304 hasConcept C141071460 @default.
- W2590931304 hasConcept C143998085 @default.
- W2590931304 hasConcept C2776694085 @default.
- W2590931304 hasConcept C2777802072 @default.
- W2590931304 hasConcept C2779013556 @default.
- W2590931304 hasConcept C2908647359 @default.
- W2590931304 hasConcept C31174226 @default.
- W2590931304 hasConcept C526805850 @default.
- W2590931304 hasConcept C71924100 @default.
- W2590931304 hasConcept C99454951 @default.
- W2590931304 hasConceptScore W2590931304C121608353 @default.
- W2590931304 hasConceptScore W2590931304C126322002 @default.
- W2590931304 hasConceptScore W2590931304C141071460 @default.
- W2590931304 hasConceptScore W2590931304C143998085 @default.
- W2590931304 hasConceptScore W2590931304C2776694085 @default.
- W2590931304 hasConceptScore W2590931304C2777802072 @default.
- W2590931304 hasConceptScore W2590931304C2779013556 @default.
- W2590931304 hasConceptScore W2590931304C2908647359 @default.
- W2590931304 hasConceptScore W2590931304C31174226 @default.
- W2590931304 hasConceptScore W2590931304C526805850 @default.
- W2590931304 hasConceptScore W2590931304C71924100 @default.
- W2590931304 hasConceptScore W2590931304C99454951 @default.
- W2590931304 hasIssue "4_suppl" @default.
- W2590931304 hasLocation W25909313041 @default.
- W2590931304 hasOpenAccess W2590931304 @default.
- W2590931304 hasPrimaryLocation W25909313041 @default.
- W2590931304 hasRelatedWork W1964567729 @default.
- W2590931304 hasRelatedWork W2051540233 @default.
- W2590931304 hasRelatedWork W2054122365 @default.
- W2590931304 hasRelatedWork W2077615248 @default.
- W2590931304 hasRelatedWork W2107314204 @default.
- W2590931304 hasRelatedWork W2122166711 @default.
- W2590931304 hasRelatedWork W2166586532 @default.
- W2590931304 hasRelatedWork W2607664512 @default.
- W2590931304 hasRelatedWork W3203896279 @default.
- W2590931304 hasRelatedWork W4283788507 @default.
- W2590931304 hasVolume "34" @default.
- W2590931304 isParatext "false" @default.
- W2590931304 isRetracted "false" @default.
- W2590931304 magId "2590931304" @default.
- W2590931304 workType "article" @default.